Kojima M, Tsutsumi N, Nagata H, Itoh F, Ujiie A, Kawashima K, Endo H, Okazaki M
Central Research Laboratory, Kissei Pharmaceutical Co., Ltd., Nagano, Japan.
Biol Pharm Bull. 1994 Apr;17(4):504-8. doi: 10.1248/bpb.17.504.
The effect of 3,9-bis(N,N-dimethylcarbamoyloxy)-5H-benzofuro[3,2-c]quinoli ne-6-one designated as KCA-098) on the bone mineral metabolism of chick embryonic bone was examined. KCA-098 dose-dependently inhibited bone resorption of cultured chick embryonic femora and calvariae. It increased the length, dry weight, and calcium and phosphorus contents of 9-d-old chick embryonic femurs cultivated for 6 d, indicating that it stimulated bone formation. These results show that KCA-098 has the unique effects of inhibiting bone resorption and stimulating bone formation of chick embryo. In addition, in an in vivo experiment, oral administration of KCA-098 (3.0 mg/kg/d) for 16 weeks led to an increase in calcium and phosphorus content as well as an increase in the amount of force required to break the femur from ovariectomized rats, suggesting that it may be useful for the treatment of bone diseases.
研究了3,9-双(N,N-二甲基氨甲酰氧基)-5H-苯并呋喃[3,2-c]喹啉-6-酮(命名为KCA-098)对鸡胚骨矿物质代谢的影响。KCA-098剂量依赖性地抑制培养的鸡胚股骨和颅骨的骨吸收。它增加了培养6天的9日龄鸡胚股骨的长度、干重以及钙和磷含量,表明它刺激了骨形成。这些结果表明,KCA-098具有抑制鸡胚骨吸收和刺激骨形成的独特作用。此外,在一项体内实验中,对去卵巢大鼠口服KCA-098(3.0毫克/千克/天)16周导致钙和磷含量增加,以及股骨骨折所需力的增加,表明它可能对治疗骨疾病有用。